Medical/Pharmaceuticals
AbbVie Employees Across Asia Unite Through Week of Possibilities by Serving and Supporting Communities
* 873 employees volunteered more than 3,600 hours across 7 Asian markets to support local communities. * Employees partnered with 21 community organizations, positively impacting more than 4,300 people through initiatives focused on patient support, inclusion, education and environmental su...
2026-07-13 10:00
2818
Deepening Collaboration in AI-Powered R&D Acceleration: Insilico Medicine and CMS announce additional collaborations in CNS diseases
SHANGHAI, July 12, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico", 03696.HK), a clinical-stage biotechnology company driven by generative artificial intelligence (AI),and China Medical System Holdings Limited ("CMS", 867.HK/8A8.SG), an open-platform innovative company linking pharmaceutical ...
2026-07-13 08:30
3840
FROM THE ALZHEIMER'S ASSOCIATION INTERNATIONAL CONFERENCE 2026
FORMER ELITE SOCCER PLAYERS SHOW EVIDENCE OF BRAIN HEALTH CHANGES IN MID-LIFE Key Takeaways * New research provides insights into brain health among former elite professional soccer players during midlife. * Former players reported high levels of depression, anxiety, and subjective difficult...
2026-07-12 12:01
3670
Priority Review Granted to PD-L1/4-1BB Bispecific Antibody Opamtistomig, Accelerating Commercialization and Addressing Unmet Need in EP-NEC
NANJING, China, July 10, 2026 /PRNewswire/ -- Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company," Stock Code: 9887.HK) today announced that the biologics license application (BLA) for Opamtistomig (LBL-024, a PD-L1/4-1BB bispecific antibody) as monotherapy for the treatment of adva...
2026-07-10 16:53
5170
Professor Gang Shen's Orthodontic Team Publishes Third Consecutive Paper in the Journal of Aligner Orthodontics
SHANGHAI, July 8, 2026 /PRNewswire/ -- Professor Gang Shen, Chief GS R&D Scientist of Smartee Denti-Technology and Chief Orthodontist at Taikang Dental, together with his orthodontic team, has published a new researcharticle titled " Pathological Mandibular Retrusion: Causality and Orthodontic Int...
2026-07-09 17:55
4298
InxMed Announces Publication in The Lancet Respiratory Medicine Featuring Promising Anticancer Activity of Ifebemtinib in combination with Garsorasib in First-Line non-small cell lung cancer (NSCLC) Harboring KRAS G12C Mutation
NANJING, China, July 9, 2026 /PRNewswire/ -- InxMed Co., Ltd ("InxMed"), a clinical-stage biotechnology company dedicated to developing innovative therapies targeting cancer treatment resistance and metastasis, today announced that the clinical results of ifebemtinib (IN10018), a highly selective...
2026-07-09 17:28
4614
WuXi Biologics' MFG8 Drug Substance Facility Secures FDA PLI Approval, Advancing Commercial Supply of a Potential Blockbuster Autoimmune Therapy
SHIJIAZHUANG, China, July 9, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that its MFG8 drug substance manufacturing facility located in Hebei has successfully passed the Pre-License Inspection (PL...
2026-07-09 15:31
4555
Groundbreaking Achievement: Study of Ensartinib as Postoperative Adjuvant Therapy Published in The New England Journal of Medicine
HANGZHOU, China, July 8, 2026 /PRNewswire/ -- On July 8, the study of Betta's ensartinib as postoperative adjuvant therapy for patients with stage IB–IIIB (T3N2M0) ALK-positive non-small cell lung cancer (NSCLC), known as the ELEVATE study,was published online in full in The New England Journal o...
2026-07-09 10:16
3486
HanchorBio Tests Broader Ambitions for HCB101 Through InxMed Partnership
Taiwan-listed biotech looks to expand the value of its lead oncology asset through combination research with late-stage cancer drug resistance specialist InxMed. TAIPEI and SHANGHAI and SAN FRANCISCO, July 8, 2026 /PRNewswire/ -- HanchorBio, Inc. (TWSE: 7827) is taking another step to broaden th...
2026-07-09 09:13
3690
Insilico Medicine Releases Positive Profit Alert for the First Half of 2026
CAMBRIDGE, Mass., July 8, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico" or the "Company", HKEX: 3696), a generative artificial intelligence (AI)-driven clinical-stage biotech company, today delivered a positive profit alert for the six months ended June 30, 2026 ("First Half of 2026"). The s...
2026-07-09 08:30
4089
Lynk Pharmaceuticals Announces First Patient Dosed in Phase II Clinical Trial of LNK01004 Ointment for Vitiligo
HANGZHOU, China, SHANGHAI and BOSTON, July 9, 2026 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. ("Lynk Pharmaceuticals"), a clinical-stage innovative drug development company focused on immune and inflammatory diseases, today announced that the first patient was successfully dosed on June 30 in...
2026-07-09 08:00
4753
On the Eve of BIO 2026, Chinese Innovative Assets Trigger a New Wave of Global Collaborations
SAN DIEGO , July 8, 2026 /PRNewswire/ -- On the eve of the highly anticipated BIO International Convention 2026, theBIOSeedin Summer Innovation Partnering Summit successfully took place in San Diego. Hosted by bioSeedin and proudly supported by strategic partners Thermo Fisher Scientific and ACRO...
2026-07-09 00:00
3315
Tsingke Highlights AI-Driven CLDN18.2 Antibody Discovery at AIS 2026
MONTPELLIER, France, July 8, 2026 /PRNewswire/ -- Tsingke, a provider of integrated life science research solutions, participated in the Antibody Industrial Symposium (AIS) 2026, one of Europe's leading conferences dedicated to therapeutic antibodies and biotherapeutics. At the event, the company...
2026-07-08 22:17
3326
Altruist Biologics' Hangzhou Antibody-Drug Conjugate Facility Receives Provincial Regulatory Approval for Segmented Production
* First antibody-drug conjugate facility to receive three provincial regulatory approvals for segmented manufacturing. * Demonstrated a unified quality system, strict risk assessment protocols, and compliance with rigorous regulatory requirements from development through commercialization. HA...
2026-07-08 22:00
3629
Seegene Launches Industry's First Global Million Clinical Study to Shape New Disease-Specific Testing Standards
* Seegene is launching the Global Million Clinical Study at the scale of one million test cases to shape disease-specific testing standards. * The study is designed to evaluate the clinical utility of syndromic PCR testing approaches and build real-world scientific evidence to support better-...
2026-07-08 21:00
3927
WuXi Biologics Achieves MSCI ESG AAA Rating and MSCI Selection Indexes Inclusion for Fourth Consecutive Year
* Maintained the highest MSCI AAA ESG Rating for the fourth consecutive year under the new ESG Model 5.0 (2026) * Included in the MSCI ESG Selection Indexes for the fourth consecutive year * Leader in Green CRDMO solutions for a healthier future SHANGHAI, July 8, 2026 /PRNewswire/ -- WuXi Bi...
2026-07-08 15:15
5836
MEDIPOST Inc. Treats First U.S. Participant in Phase III Trial of Umbilical Cord Stem Cell Therapy for Symptomatic Cartilage Defects Due to Knee Osteoarthritis
U.S. Phase III Trial Expands Clinical Investigation of Stem Cell Therapy for Knee Cartilage Defects CAMBRIDGE, Mass., July 8, 2026 /PRNewswire/ -- MEDIPOST Inc., a biotechnology company developing allogeneic, umbilical cord blood-derived stem cell therapies for inflammation-driven degenerative d...
2026-07-08 10:43
3471
Wegovy® (semaglutide) label updated in Singapore with higher dose supported by STEP UP evidence
* Up to one in three participants on semaglutide 7.2 mg achieved at least 25% weight loss over 72 weeks * Mean weight loss with semaglutide 7.2 mg reached 21%, reflecting overall treatment efficacy * Up to 84% of weight loss was driven by reductions in fat mass, supporting meaningful improv...
2026-07-08 09:22
2969
Insilico Initiates Phase III Clinical Trial for Rentosertib, Its AI-Empowered TNIK Inhibitor for Idiopathic Pulmonary Fibrosis
* Potentially first-in-class oral TNIK inhibitor advances into late-stage development after milestones marked by vital peer-reviewed papers: the discovery-to-clinic journey in Nature Biotechnology, and positive Phase IIa clinical results in Nature Medicine * Rentosertib represents a novel mec...
2026-07-07 21:43
5077
Piramal Pharma's FY2026 Annual Report showcases global scale, innovation-led growth and sustainability milestones
MUMBAI, India, July 7, 2026 /PRNewswire/ -- Piramal Pharma Limited (PPL) (NSE: PPLPHARMA) (BSE: 543635), a leading global pharmaceutical, health and wellness company, released its Annual Report for FY2026, highlighting a year of strengthening its global platform, investing in differentiated capab...
2026-07-07 20:50
4746
Week's Top Stories
Most Reposted
SMU School of Accountancy launches Applied AI Track for next generation of accounting and finance professionals
[Picked up by 282 media titles]
2026-10-07 11:50DayOne Files Registration Statement for Proposed Initial Public Offering
[Picked up by 279 media titles]
2026-10-06 05:28Agoda Partners with Marina Bay Sands on Bespoke Flagship Store for Experience-Led Travel
[Picked up by 277 media titles]
2026-10-08 09:50
New Asia Forum Targets US$30 Billion in Investment into the New Asia at Its Inaugural Edition in Bali
[Picked up by 274 media titles]
2026-10-09 13:21The Coffee Bean & Tea Leaf® Turns 63 and Sets a New Direction for Its Next Chapter of Growth
[Picked up by 263 media titles]
2026-10-05 13:24
Most Read
Nuix Neo Generative AI Framework
2026-10-08 08:02
9147
Silicon Quantum Computing Named to Fast Company's 2026 Next Big Things in Tech List
2026-10-06 19:38
8215
DayOne Files Registration Statement for Proposed Initial Public Offering
2026-10-06 05:28
8152